Table 2.
Selected clinical trials of different therapeutic strategies in CML.
| Drug | Class/Mechanism of Action | NCT Number | Scheme | Phase |
|---|---|---|---|---|
| BCR-ABL1 therapies | ||||
| Asciminib | ABL1 myristoyl pocket inhibitor | NCT02081378 | Mono. and Comb. TKI | 1 |
| NCT03595917 | Plus Dasatinib | 1 | ||
| NCT03906292 | Mono. and Comb. TKI | 2 | ||
| NCT03578367 | Plus Imatinib | 2 | ||
| NCT03106779 | Mono. | 3 | ||
| NCT04971226 | Mono. | 3 | ||
| NCT04948333 | Mono. | 3 | ||
| NCT04877522 | Mono. and Comb. TKI | 3 | ||
| NCT04795427 | Mono. | 2 | ||
| NCT04666259 | Mono. | 3 | ||
| Flumatinib | BCR-ABL1 ATP-binding site inhibitor | NCT04677439 | Mono. | 4 |
| NCT04933526 | Mono. | 4 | ||
| PF-114 | BCR-ABL1 ATP-binding site inhibitor | NCT02885766 | Mono. | 1/2 |
| HQP1351 | BCR-ABL1 ATP-binding site inhibitor | NCT03883100 | Mono. | 2 |
| NCT03883087 | Mono. | 2 | ||
| NCT04126681 | Mono. | 2 | ||
| NCT04260022 | Mono. | 1 | ||
| Vodobatinib | BCR-ABL1 ATP-binding site inhibitor | NCT02629692 | Mono. | 1/2 |
| Non BCR-ABL1 therapies | ||||
| BP1001 | GRB2 antisense oligonucleotide | NCT01159028 | Mono. | 1 |
| NCT02923986 | Plus Dasatinib | 2 | ||
| Tipifarnib | Farnesyltransferase inhibitor | NCT00004009 | Mono. | 1 |
| Lonafarnib | Farnesyltransferase inhibitor | NCT00047502 | Plus Imatinib | 1 |
| Selumetinib | MEK inhibitors | NCT03326310 | Plus Azacitidine | 1 |
| Ruxolitinib | JAK2 inhibitor | NCT03610971 | Comb. TKI | 2 |
| NCT01702064 | Plus Nilotinib | 1 | ||
| Everolimus | mTOR inhibitor | NCT00081874 | Mono. | 1/2 |
| NCT01188889 | Plus Imatinib | 2 | ||
| Sirolimus | mTOR inhibitor | NCT00776373 | Plus Citarabine | 1/2 |
| Venetoclax | BCL-2 inhibitor | NCT02689440 | Plus Dasatinib | 2 |
| NCT04188405 | Plus Ponatinib, Decitabine | 2 | ||
| NCT03576547 | Plus Ponatinib, corticosteroids | 1/2 | ||
| AMG-232 | MDM2 inhibitor | NCT04835584 | Mono. | 1/2 |
| Sonidigib | SHH inhibitor | NCT01456676 | Plus Nilotinib | 1 |
| Pioglitazone | PPAR-γ inhibitor | NCT02852486 | Plus Imatinib | 2 |
| NCT02767063 | Plus TKI | 1/2 | ||
| NCT02889003 | Plus TKI | 2 | ||
| Epigenetic modulators | ||||
| Azacitidine | Hypomethylating agent | NCT03895671 | Plus Ponatinib | 2 |
| NCT01460498 | Plus TKI | 1 | ||
| Panobinostat | Histone Deacetylase Inhibitor | NCT00451035 | Mono. | 1 |
| Immunotherapies | ||||
| Peg-IFNα | Pegylated Interferon alpha | NCT01866553 | Plus Nilotinib | 2 |
| NCT01872442 | Plus Dasatinib | 2 | ||
| NCT03831776 | Plus Bosutinib | 2 | ||
| Nivolumab | Anti-PD-1 antibody | NCT02011945 | Plus Dasatinib | 1 |
| NCT01822509 | Plus Ipilimumab | 1 | ||
| Pembrolizumab | Anti-PD-1 antibody | NCT03516279 | Plus TKI | 2 |
| DC vaccine | Dendritic cells vaccine | NCT02543749 | Mono. | 1/2 |
| CLL1-CD33 cCART | compound CAR (cCAR) T cells | NCT03795779 | Mono. | 1 |
| KDS-1001 | natural killer cell therapy | NCT04808115 | Plus TKI | 1 |
Comb: combination; Mono: monotherapy; NCT: national clinical trial number; TKI: tyrosine kinase inhibitors.